Fredag 6 Juni | 18:38:12 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2025-11-27 08:00 Kvartalsrapport 2025-Q3
2025-08-28 08:00 Kvartalsrapport 2025-Q2
2025-06-25 N/A X-dag ordinarie utdelning PRLD 0.00 SEK
2025-06-24 N/A Årsstämma
2025-05-30 - Kvartalsrapport 2025-Q1
2025-02-28 - Bokslutskommuniké 2024
2024-11-27 - Kvartalsrapport 2024-Q3
2024-08-28 - Kvartalsrapport 2024-Q2
2024-05-27 - Årsstämma
2024-05-17 - Kvartalsrapport 2024-Q1
2024-05-15 - X-dag ordinarie utdelning PRLD 0.00 SEK
2024-02-21 - Bokslutskommuniké 2023
2023-11-27 - Extra Bolagsstämma 2023
2023-11-27 - Kvartalsrapport 2023-Q3
2023-08-29 - Kvartalsrapport 2023-Q2
2023-05-12 - X-dag ordinarie utdelning PRLD 0.00 SEK
2023-05-11 - Årsstämma
2023-05-11 - Kvartalsrapport 2023-Q1
2023-02-21 - Bokslutskommuniké 2022
2022-11-30 - Kvartalsrapport 2022-Q3
2022-08-29 - Kvartalsrapport 2022-Q2
2022-08-04 - Extra Bolagsstämma 2022
2022-05-23 - X-dag ordinarie utdelning PRLD 0.00 SEK
2022-05-20 - Årsstämma
2022-05-20 - Kvartalsrapport 2022-Q1
2022-02-22 - Bokslutskommuniké 2021
2021-11-23 - Kvartalsrapport 2021-Q3
2021-08-31 - Kvartalsrapport 2021-Q2
2021-05-06 - X-dag ordinarie utdelning PRLD 0.00 SEK
2021-05-05 - Årsstämma
2021-05-05 - Kvartalsrapport 2021-Q1
2021-02-24 - Bokslutskommuniké 2020
2020-11-17 - Kvartalsrapport 2020-Q3
2020-08-28 - Kvartalsrapport 2020-Q2
2020-05-21 - X-dag ordinarie utdelning PRLD 0.00 SEK
2020-05-20 - Årsstämma
2020-05-14 - Kvartalsrapport 2020-Q1
2020-02-13 - Bokslutskommuniké 2019
2019-11-20 - Kvartalsrapport 2019-Q3
2019-08-28 - Kvartalsrapport 2019-Q2
2019-05-16 - Årsstämma
2019-05-16 - Kvartalsrapport 2019-Q1
2019-05-10 - X-dag ordinarie utdelning PRLD 0.00 SEK
2018-11-20 - Kvartalsrapport 2018-Q3
2018-08-28 - Kvartalsrapport 2018-Q2
2018-05-17 - X-dag ordinarie utdelning PRLD 0.00 SEK
2018-05-16 - Årsstämma
2018-05-16 - Kvartalsrapport 2018-Q1
2018-02-14 - Bokslutskommuniké 2017
2017-11-23 - Kvartalsrapport 2017-Q3
2017-08-25 - Kvartalsrapport 2017-Q2
2017-05-22 - X-dag ordinarie utdelning PRLD 0.00 SEK
2017-05-19 - Årsstämma
2017-05-19 - Kvartalsrapport 2017-Q1

Beskrivning

LandSverige
ListaNordic SME Sweden
SektorHälsovård
IndustriMedicinteknik
Prolight Diagnostics utvecklar testsystem inom POCT (Point of care testning). Testerna används utanför sjukhuslaboratorium för att möjliggöra snabba bedömningar av patienters hälsa. Bolagets POCT-Plattform är i utveckling med avsikt att mäta flera biomarkörer samtidigt. En viktig del i arbetet är således att korta ner tiden för provresultaten, särskilt viktigt för patienter med hjärtbesvär. Bolaget grundades år 1999 och har sitt huvudkontor i Lund.
2025-06-04 09:30:00

Prolight Diagnostics (“Prolight” or the “Company”) hereby announces that additional existing shareholders and external investors have submitted subscription commitments totaling 2.9 MSEK for the upcoming rights issue of shares (the “Rights Issue”) that Prolight resolved on, subject to approval by the subsequent extraordinary general meeting, on May 21, 2025. Including these new subscription commitments, the Rights Issue is now covered by subscription commitments amounting to approximately 16.2 MSEK, corresponding to approximately 16.1 percent of the Rights Issue, of which 9.9 MSEK is represented by a subscription commitment from the Company’s UK-based instrument contract manufacturer ITL, corresponding to approximately 9.8 percent of the Rights Issue. In addition to its subscription commitment, ITL has undertaken not to sell or transfer any shares before September 30, 2026, under a lock-up agreement.

Subscription commitments
As previously announced, all members of the Board and management team, as well as most of the Company’s employees, have committed to subscribe for shares amounting to a total of approximately SEK 3.4 million. Of this amount, the Company’s CEO and Board member Ulf Bladin has committed to subscribe for shares worth SEK 1 million. In addition, ITL has committed to subscribe for shares amounting to SEK 9.9 million, with payment to be made through set-off against future costs associated with the completion of the instrument development and the production of pilot instruments to be used in the clinical performance study.

In addition to the previously communicated subscription commitments, the Company can now announce that further existing shareholders and external investors have submitted subscription commitments totaling approximately SEK 2.9 million, corresponding to approximately 2.9 percent of the Rights Issue. These existing shareholders and external investors have expressed a strong long-term interest in the Company, ahead of a period marked by significant milestones such as the whole blood study at St. Thomas’ Hospital, intensified partnership discussions, and commercialization in 2026.

In total, the Rights Issue is thus covered by subscription commitments amounting to approximately SEK 16.2 million, corresponding to approximately 16.1 percent of the Rights Issue. No compensation will be paid for the submitted subscription commitments. The commitments are not secured pledged assets, restricted funds or similar arrangements.

Lock-up agreement

In addition to the subscription commitment, ITL has undertaken to the Company not to sell or transfer shares before September 30, 2026, under a lock-up agreement. The lock-up undertaking covers all shares that ITL's subscription commitment corresponds to.

Indicative timetable

June 10, 2025Last trading day in the share with the right to participate in the Rights Issue
June 10, 2025Extra general meeting
June 11, 2025First trading day in the share without the right to participate in the Rights Issue
June 12, 2025Record date for receipt of subscription rights. Shareholders registered in the share register maintained by Euroclear Sweden AB on this date will receive subscription rights for participation in the Rights Issue.
June 13, 2025Publication of the Information Document
June 16 – June 25, 2025Trading in subscription rights (TR) on NGM
June 16 – June 30, 2025Subscription period in the Rights Issue
June 16 – July 16, 2025Expected trading in paid subscribed shares
(BTA) on NGM
July 2, 2025Estimated date for announcement of issue outcome

Advisors
Mangold Fondkommission AB is financial advisor and Advokatfirman Lindahl KB is legal advisor to the Company in connection with the Rights Issue.